HIPRA is taking part in a European consortium led by the Medical University of Vienna to develop a next-generation intranasal flu vaccine, including protection against strains with pandemic potential. The project has been submitted to HaDEA and aims to receive funding from the EU4Health programme. HIPRA contributes its industrial leadership by managing production, regulatory processes, and future commercialization. In addition, it co-leads process and analytical development to ensure a robust transition from research to production.